Not Yet RecruitingNot Applicable

Resveratrol Effects on Inflammatory Biomarkers and Cardiometabolic Parameters.

Chile75 participantsStarted 2026-04-01

Plain-language summary

This study aims to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers and cardiometabolic parameters in community-dwelling adults

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Comunnity-dwelling persons. * Any ethnicity. * With willingness to consume the bar daily during the intervention period. Exclusion Criteria: * Allergy/intolerance to ingredients in the bar. * Pregnancy or breastfeeding. * Use of antioxidant/polymeroid supplements in the last 4 weeks. * Unstable chronic diseases (e.g., severe liver failure, advanced kidney failure, active cancer). * Persons in treatments that strongly interfere with polyphenol metabolism (e.g., antibiotics, anti-inflammatories, corticosteroids, anti-allergy medication). * Persons with metal prosthesis. * Persons undergoing or waiting for metabolic bariatric surgery. * Persons with scheduled digestive surgery within the next 8 weeks * Persons in recent treatments for hypertension (less than 3 month). * Participation in another clinical trial.

What they're measuring

Inflammatory biomarkers: Total plasma antioxidant capacity (µmol/L).

Timeframe: From enrollment to the end of treatment at 8 weeks

Inflammatory Biomarkers: Ultra-sensitivity CRP (mg/L).

Timeframe: From enrollment to the end of treatment at 8 weeks

Inflammatory Biomarkers: IL-6 (pg/mL).

Timeframe: From enrollment to the end of treatment at 8 weeks

Inflammatory Biomarkers: Plasma malondialdehyde (µmol/L).

Timeframe: From enrollment to the end of treatment at 8 weeks

Inflammatory Biomarkers: TNF-alfa (pg/mL).

Timeframe: From enrollment to the end of treatment at 8 weeks

Inflammatory Biomarkers: Advanced glycation end-products (AGEs) in 1 to 5 units.

Timeframe: From enrollment to the end of treatment at 8 weeks

Trial details

NCT IDNCT07395921

SponsorCenter for Research and Innovation Viña Concha y Toro

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-08-31

Contact for this trial

Ileana González Bonet, Dr

+56 71 2986000 ileanag@ucm.cl

View on ClinicalTrials.gov More Inflammation Biomarkers trials

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Inflammatory biomarkers: Total plasma antioxidant capacity (µmol/L).

Timeframe: From enrollment to the end of treatment at 8 weeks

Inflammatory Biomarkers: Ultra-sensitivity CRP (mg/L).

Timeframe: From enrollment to the end of treatment at 8 weeks

Inflammatory Biomarkers: IL-6 (pg/mL).

Timeframe: From enrollment to the end of treatment at 8 weeks

Inflammatory Biomarkers: Plasma malondialdehyde (µmol/L).

Timeframe: From enrollment to the end of treatment at 8 weeks

Inflammatory Biomarkers: TNF-alfa (pg/mL).

Timeframe: From enrollment to the end of treatment at 8 weeks

Inflammatory Biomarkers: Advanced glycation end-products (AGEs) in 1 to 5 units.

Timeframe: From enrollment to the end of treatment at 8 weeks